| Literature DB >> 29691153 |
Khushbu Shah1, Xin Lin1, Sherry F Queener2, Vivian Cody3, Jim Pace3, Aleem Gangjee4.
Abstract
To combine the potency of trimetrexate (TMQ) or piritrexim (PTX) with the species selectivity of trimethoprim (TMP), target based design was carried out with the X-ray crystal structure of human dihydrofolate reductase (hDHFR) and the homology model of Pneumocystis jirovecii DHFR (pjDHFR). Using variation of amino acids such as Met33/Phe31 (in pjDHFR/hDHFR) that affect the binding of inhibitors due to their distinct positive or negative steric effect at the active binding site of the inhibitor, we designed a series of substituted-pyrrolo[2,3-d]pyrimidines. The best analogs displayed better potency (IC50) than PTX and high selectivity for pjDHFR versus hDHFR, with 4 exhibiting a selectivity for pjDHFR of 24-fold.Entities:
Keywords: DHFR inhibitors; Opportunistic infections; Pneumocystis pneumonia; Pyrrolo[2,3-d]pyrimidines; hDHFR; pjDHFR
Mesh:
Substances:
Year: 2018 PMID: 29691153 PMCID: PMC5967623 DOI: 10.1016/j.bmc.2018.04.032
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641